2
Announcements
Trials
Browse
Landscape
Status
Completed
230
Terminated
72
Recruiting
55
Active not recruiting
30
Withdrawn
22
Unknown
10
Not yet recruiting
7
Available
2
Suspended
1
No longer available
1
Sponsor Class
INDUSTRY
2
Study Type
Expanded_access
2
Sponsor
Cancer Type
Myeloid
2
Sarcoma
1
Plasma cell
1
Lymphoid
1
Gynecologic
1
Conditions
Neoplasms
14
Carcinoma, Non-Small-Cell Lung
8
Sarcoma
6
Prostatic Neoplasms
6
Pancreatic Neoplasms
6
Neuroblastoma
6
Multiple Myeloma
6
Recurrence
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Melanoma
5
Ovarian Neoplasms
4
Leukemia, Myeloid, Acute
4
Glioblastoma
4
Breast Neoplasms
4
Stomach Neoplasms
3
Small Cell Lung Carcinoma
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma
3
Hematologic Neoplasms
3
Head and Neck Neoplasms
3
Urinary Bladder Neoplasms
2
Primary Myelofibrosis
2
Pheochromocytoma
2
Osteosarcoma
2
Non-Muscle Invasive Bladder Neoplasms
2
Neuroectodermal Tumors, Primitive
2
Neoplasm Metastasis
2
Myelodysplastic Syndromes
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, Non-Hodgkin
2
Interventions
selinexor
1
ruxolitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Available
×
Primary Myelofibrosis
×
Clear all
NCT07215832
2026-03-02
KEAP
Karyopharm Therapeutics Inc
Available
NCT04745637
2025-11-18
Managed Access Programs for INC424, Ruxolitinib
Novartis
Available